Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Margaret T. Kasner"'
Autor:
Zachary T. Elliott, Zachary Goldberg, Ramez Philips, Jennifer M. Johnson, Margaret T. Kasner, William K. Kelly, Sarah Osipowicz, Rachael Dampman, Joseph M. Curry
Publikováno v:
Clinics and Practice, Vol 12, Iss 5, Pp 692-700 (2022)
Progress in the management of rare diseases, including rare cancers, is dependent upon clinical trials; however, as many as 32% of rare-disease trials go uncompleted or unpublished due to insufficient accrual. Monitoring practices may differ between
Externí odkaz:
https://doaj.org/article/a054b194539e432596ee7306284b1d2e
Autor:
Margaret T. Kasner
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/2e1da8eb2f124bdbaa517eff69f0bed5
Purpose: Integration of signal transduction inhibitors into chemotherapy regimens generally has generally not led to anticipated increases in response and survival. However, it remains unclear whether this is because of inadequate or inconsistent inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81460db00d39c5fe135d9e89e4e802c9
https://doi.org/10.1158/1078-0432.c.6520673
https://doi.org/10.1158/1078-0432.c.6520673
CCR Translation for This Article from Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::271edb1cfd0a9769822a0a8682a8b763
https://doi.org/10.1158/1078-0432.22446191
https://doi.org/10.1158/1078-0432.22446191
Autor:
Margaret T. Kasner, Molly B. Halloran, Jonathan Pan, Ellen K. Ritchie, Gerald J. Fetterly, Douglas Kramer, David G. Hangauer, James E. Thompson
Publikováno v:
Investigational New Drugs. 40:773-781
Background Poor tolerance to standard therapies and multi-drug resistance complicate treatment of elderly patients with acute myeloid leukemia (AML). It is therefore imperative to explore novel tolerable agents and target alternative pathways. KX2-39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5f2a25ec450646d7e7038c465c57784
https://doi.org/10.1007/s10637-022-01255-1
https://doi.org/10.1007/s10637-022-01255-1